Compare HERE & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HERE | TLSA |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | China | United Kingdom |
| Employees | 714 | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.1M | 155.3M |
| IPO Year | N/A | 2017 |
| Metric | HERE | TLSA |
|---|---|---|
| Price | $2.25 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 164.2K | ★ 284.0K |
| Earning Date | 06-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.29 | N/A |
| P/E Ratio | $2.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $1.04 |
| 52 Week High | $5.80 | $2.60 |
| Indicator | HERE | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 32.89 |
| Support Level | $2.03 | N/A |
| Resistance Level | $2.50 | $1.61 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 73.50 | 9.43 |
Here Group Ltd is dedicated to creating collectible pop toys that evoke joy and emotional resonance. The group design and compelling storytelling, which provide users with a collecting experience that blends artistic value with emotional warmth, continuously convey a joyful and immersive brand culture. Adhering to the brand philosophy of joy, integrity, wonder, and co-creation, the company is building a vibrant ecosystem connecting creativity and emotion, working hand-in-hand with overall toy enthusiasts to create, share, and transmit dreams.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.